The US Food and Drug Administration says it stopped conducting inspections in China after the State Department on 30 January issued a warning against traveling there due to the novel coronavirus now called SARS-CoV-2.
US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.
More from Compliance
More from Pink Sheet
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.